Lu Meng, Miao Yi, Qi Lan, Bai Mingzhu, Zhang Jiarong, Feng Youji
Department of Obstetrics and Gynecology, Shanghai General Hospital of Nanjing Medical University, Shanghai, China.
Oncol Res. 2016;23(6):267-74. doi: 10.3727/096504016X14549667333963.
FKBP14 belongs to the family of FK506-binding proteins (FKBPs). Altered expression of FKBPs has been reported in several malignancies. This study aimed to reveal the expression profile of FKBP14 in ovarian cancer and evaluate whether FKBP14 is a molecular target for cancer therapy. We found that the FKBP14 mRNA level was significantly higher in ovarian cancer tissues than in normal tissues. FKBP14 expression was then knocked down in two ovarian cancer cell lines, SKOV3 and HO8910 cells, by a lentiviral short hairpin RNA (shRNA) delivery system. Reduced expression of FKBP14 markedly impaired the proliferative ability of ovarian cancer cells. Additionally, ovarian cancer cells infected with FKBP14 shRNA lentivirus tended to arrest in the G0/G1 phase and undergo apoptosis. Moreover, knockdown of FKBP14 induced cell apoptosis via increasing the ratio of Bax to Bcl-2. These results indicated that FKBP14 might be a diagnostic marker for ovarian cancer and could be a potential molecular target for the therapy of ovarian cancer.
FKBP14属于FK506结合蛋白(FKBPs)家族。已有报道称FKBPs在多种恶性肿瘤中表达改变。本研究旨在揭示FKBP14在卵巢癌中的表达谱,并评估FKBP14是否为癌症治疗的分子靶点。我们发现,卵巢癌组织中FKBP14 mRNA水平显著高于正常组织。然后,通过慢病毒短发夹RNA(shRNA)递送系统在两种卵巢癌细胞系SKOV3和HO8910细胞中敲低FKBP14表达。FKBP14表达降低显著损害了卵巢癌细胞的增殖能力。此外,感染FKBP14 shRNA慢病毒的卵巢癌细胞倾向于停滞在G0/G1期并发生凋亡。此外,敲低FKBP14通过增加Bax与Bcl-2的比值诱导细胞凋亡。这些结果表明,FKBP14可能是卵巢癌的诊断标志物,并且可能是卵巢癌治疗的潜在分子靶点。